Applied DNA to Speak on COVID-19 Panel at Maxim Group’s Infectious Disease Virtual Conference on May 5
April 14 2020 - 8:30AM
Business Wire
Applied DNA Sciences, Inc. (NASDAQ:APDN) (“Applied DNA” or the
“Company”), a leader in Polymerase Chain Reaction (PCR)-based DNA
manufacturing that enables diagnostics, pre-clinical nucleic
acid-based therapeutic drug candidates, supply chain security,
anti-counterfeiting and anti-theft technology, today announced its
participation at Maxim Group’s Infectious Disease Virtual
Conference on May 5, 2020. Applied DNA CEO Dr. James Hayward will
join a panel of drug developers to share his insights on how
gene-based vaccines, such as those being advanced by the Company
and its joint development partner, Rome, Italy-based Takis Biotech,
are at the forefront of COVID-19 vaccine development programs. The
panel, entitled ‘COVID-19 (Vaccine, Treatment, Testing)’, is
scheduled for 2:00 p.m. ET to 3:30 p.m. ET. To RSVP for the virtual
conference, please click through: Maxim Group’s Infectious Disease
Virtual Conference.
Applied DNA’s COVID-19 development program spans both vaccine
candidates and a diagnostic assay kit to enable mass testing of the
SARS-CoV-2, the virus that causes the disease COVID-19. Together
with Takis Biotech, the Company is currently progressing five
vaccine candidates that are based on COVID-19’s ‘spike’ protein.
Utilizing LinearDNA™, its proprietary and patent-protected platform
for large-scale DNA manufacture by PCR, the Company expects to
complete production of all candidate vaccines in April 2020 and for
preclinical animal testing by Takis Biotech to begin in late April
2020. Concurrently, the Company has begun manufacturing of a
high-sensitivity Research Use Only (RUO) diagnostic assay kit for
SARS-CoV-2 and plans to seek eventual approval under the U.S.
Federal Drug Administration’s Emergency Use Authorizations.
Dr. Hayward will hold one-on-one meetings with institutional
investors through Maxim Group. To schedule a one-on-one meeting,
please contact sdorce@maximgrp.com.
Applied DNA makes clear that no commercial partner has been
identified to take the coronavirus vaccine candidates or diagnostic
under development to market nor is there any indication that the
Company’s vaccine candidates or diagnostic would be approved by
regulators.
About Applied DNA Sciences
Applied DNA is a provider of molecular technologies that enable
supply chain security, anti-counterfeiting and anti-theft
technology, product genotyping and pre-clinical nucleic acid-based
therapeutic drug candidates.
LinearDNA™ is a trademark of Applied DNA Sciences, Inc.
Visit adnas.com for more information. Follow us on Twitter and
LinkedIn. Join our mailing list.
The Company’s common stock is listed on NASDAQ under ticker
symbol ‘APDN’, and its publicly-traded warrants are listed on OTC
under ticker symbol ‘APPDW’.
Forward-Looking Statements
The statements made by Applied DNA in this press release may be
“forward-looking” in nature within the meaning of Section 27A of
the Securities Act of 1933, Section 21E of the Securities Exchange
Act of 1934 and the Private Securities Litigation Reform Act of
1995. Forward-looking statements describe Applied DNA’s future
plans, projections, strategies and expectations, and are based on
assumptions and involve a number of risks and uncertainties, many
of which are beyond the control of Applied DNA. Actual results
could differ materially from those projected due to the possibility
of a failure to make timely payment on its outstanding secured
convertible notes and resulting enforcement by noteholders of
remedies on collateral which includes substantially all of Applied
DNA’s assets, its history of net losses, limited financial
resources, limited market acceptance, the fact that there has never
been a commercial drug product utilizing PCR-produced DNA
technology approved for therapeutic use, the uncertainties inherent
in research and development, future clinical data and analysis,
including whether any of Applied DNA’s or its partners product
candidates will advance further in the preclinical research or
clinical trial process, including receiving clearance from the U.S.
Food and Drug Administration or equivalent foreign regulatory
agencies to conduct clinical trials and whether and when, if at
all, they will receive final approval from the U.S. FDA or
equivalent foreign regulatory agencies, the unknown outcome of any
applications to U.S. FDA or equivalent regulatory agencies and
various other factors detailed from time to time in Applied DNA’s
SEC reports and filings, including our Annual Report on Form 10-K
filed on December 12, 2019 and our subsequent quarterly report on
Form 10-Q filed on February 6, 2020, and other reports we file with
the SEC, which are available at www.sec.gov. Applied DNA undertakes
no obligation to update publicly any forward-looking statements to
reflect new information, events or circumstances after the date
hereof or to reflect the occurrence of unanticipated events, unless
otherwise required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200414005148/en/
Investors: Sanjay M. Hurry, LHA Investor Relations,
212-838-3777, shurry@lhai.com Web: www.adnas.com |
twitter: @APDN
Applied DNA Sciences (NASDAQ:APDN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Applied DNA Sciences (NASDAQ:APDN)
Historical Stock Chart
From Apr 2023 to Apr 2024